Patents by Inventor Christophe Denis Adelinet

Christophe Denis Adelinet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinolinone derivatives as PARP and tank inhibitors
    Patent number: 8778966
    Abstract: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 15, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Jorge Eduardo Vialard, Patrick René Angibaud, Laurence Anne Mevellec, Christophe Meyer, Eddy Jean Edgard Freyne, Isabelle Noëlle Constance Pilatte, Bruno Roux, Elisabeth Thèrése Jeanne Pasquier, Xavier Marc Bourdrez, Christophe Denis Adelinet, Laurence Françoise Bernadette Marconnet-Decrane, Jacqueline Anne Macritchie, James Edward Stewart Duffy, Andrew Pate Owens, Pierre-Henri Storck, Virginie Sophie Poncelet
  • QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS
    Publication number: 20130018017
    Abstract: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Jorge Eduardo VIALARD, Patrick René ANGIBAUD, Laurence Anne MEVELLEC, Christophe MEYER, Eddy Jean Edgard FREYNE, Isabelle Noëlle Constance PILATTE, Bruno ROUX, Elizabeth Thérèse Jeanne PASQUIER, Xavier Marc BOURDREZ, Christophe Denis ADELINET, Laurence Françoise Bernadette MARCONNET-DECRANE, Jacqueline Anne MACRITCHIE, James Edward Stewart DUFFY, Andrew Pate OWENS, Pierre-Henri STORCK, Virginie Sophie PONCELET
  • Quinolinone derivatives as PARP and TANK inhibitors
    Patent number: 8299256
    Abstract: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: October 30, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jorge Eduardo Vialard, Patrick René Angibaud, Laurence Anne Mevellec, Christophe Meyer, Eddy Jean Edgard Freyne, Isabelle Noëlle Constance Pilatte, Bruno Roux, Elisabeth Thérèse Jeanne Pasquier, Xavier Marc Bourdrez, Christophe Denis Adelinet, Laurence Françoise Bernadette Marconnet-Decrane, Jacqueline Anne Macritchie, James Edward Stewart Duffy, Andrew Pate Owens, Pierre-Henri Storck, Virginie Sophie Poncelet
  • QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS
    Publication number: 20100168065
    Abstract: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
    Type: Application
    Filed: March 7, 2008
    Publication date: July 1, 2010
    Applicant: Janssen Pharmaceutica NV
    Inventors: Jorge Eduardo Vialard, Patrick René Angibaud, Laurence Anne Mevellec, Christophe Meyer, Eddy Jean Edgard Freyne, Isabelle Noëlle Pilatte, Bruno Roux, Elisabeth Thérèse Jeanne Pasquier, Xavier Marc Bourdrez, Christophe Denis Adelinet, Laurence Francoise Bernadette Marconnet-Decrane, Jacqueline Anne Macritchie, James Edward Stewart Duffy, Andrew Pate Owens, Pierre-Henri Storck, Virginie Sophie Poncelet
  • Retinoic acid mimetic anilides
    Patent number: 7579352
    Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or —NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: August 25, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Dominique Mabire, Christophe Denis Adelinet, Imré Christian Csoka, Marc Gaston Venet
  • Retinoic acid mimetic anilides
    Patent number: 7179825
    Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; or R1 and R2 taken together may form a bivalent radical of formula —(CH2)n— wherein n is 2, 3, 4, 5 or 6; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or —NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (a
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: February 20, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Dominique Mabire, Christophe Denis Adelinet, Imré Christian Csoka, Marc Gaston Venet
  • Retinoic acid mimetic anilides
    Patent number: 6936626
    Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; or R1 and R2 taken together may form a bivalent radical of formula —(CH2)n— wherein n is 2, 3, 4, 5 or 6; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk—NR3R5 (i) or —NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (a
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: August 30, 2005
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Dominique Mabire, Christophe Denis Adelinet, Imré Christian Csoka, Marc Gaston Venet
  • Retinoic acid mimetic anilides
    Publication number: 20020115653
    Abstract: The present invention is concerned with compounds of formula 1
    Type: Application
    Filed: September 25, 2001
    Publication date: August 22, 2002
    Inventors: Dominique Mabire, Christophe Denis Adelinet, Imre Christian Csoka, Marc Gaston Venet
  • Retinoic acid mimetic anlides
    Patent number: 6319939
    Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; or R1 and R2 taken together may form a bivalent radical of formula —(CH2)n— wherein n is 2, 3, 4, 5 or 6; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or —NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alk
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: November 20, 2001
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Dominique Mabire, Christophe Denis Adelinet, Imré Christian Csoka, Marc Gaston Venet